#USA #New York #CAR T Therapy #Genentech #Lupus Research

Pioneering New Horizons in Lupus Treatment with CAR T Cell Therapy

The Lupus Research Alliance (LRA), the largest private funder of lupus research globally, has partnered with Genentech, a member of the Roche Group, to announce the inaugural recipients of the Lupus Research Alliance-Genentech Award on Immune Resetting Therapies for Lupus (LGA-IRT). This collaboration aims to advance the understanding of engineered cell therapies, which offer the potential to reprogram the immune system and establish long-lasting remission for individuals with lupus.

Exploring CAR-T Cell Therapy

This year's award recipients are focused on studying chimeric antigen receptor (CAR)-T cell therapy, a method that has achieved remarkable outcomes in cancer treatment and is now being investigated for severe lupus cases. In existing clinical trials, some lupus patients who received CD19-targeted CAR-T cells and had previously shown resistance to standard treatments exhibited rapid and deep remission, providing them the opportunity to discontinue other lupus medications. This innovative therapy operates by reprogramming a patient's immune T cells to target and eliminate B cells essential in the pathogenesis of lupus.

While the results are promising, they also raise significant scientific inquiries regarding the immune system reset induced by CAR-T therapy. Researchers are delving into questions such as what mechanisms allow some patients to maintain their remission longer than others, and why the disease might return in certain individuals. The collaborative research funded by this program seeks to address these critical queries.

Teodora Staeva, PhD, Chief Scientific Officer of the LRA, highlighted the importance of a solid scientific foundation for transitioning from pioneering clinical trials to viable therapies: "By supporting these studies in conjunction with Genentech, we aim to enrich our understanding of immune resetting, with the ultimate goal of enhancing the safety and durability of these transformative therapies for those afflicted by lupus."

Funding for Research and Collaboration

This program allocates $150,000 annually for up to two years for each research initiative, targeting the development of effective and accessible immune-resetting therapies for lupus patients. The three projects funded under this auspice promise to provide deeper insights into therapeutic strategies that could vastly improve treatment outcomes:

1. Anne Davidson, MBBS, The Feinstein Institutes for Medical Research: Dr. Davidson's research investigates the cellular mechanisms behind CAR-T cell therapy and its long-term remission effects in lupus patients. By utilizing mouse models, her research aims to identify whether certain antibody-producing plasma cells resistant to CAR-T therapy and persistent underlying inflammation might underpin relapses.

2. Panagiotis Garantziotis, MD, PhD, Uniklinikum Erlangen: Dr. Garantziotis examines blood and bone marrow samples from lupus patients treated with CAR-T therapy compared to those receiving conventional B cell-targeting treatments. His focus is on how CAR-T therapy alters the immune system's architecture, potentially offering explanations for its efficacy and guiding the creation of safer treatments.

3. Eric Meffre, PhD, Stanford University: Dr. Meffre looks into how CAR-T therapy might restore immune tolerance that typically prevents the generation of self-reactive B cells. His investigation will clarify whether CAR-T therapy rectifies the fundamental issues leading to lupus or merely strengthens existing regulatory mechanisms.

Education and Awareness on Lupus

Lupus remains a chronic and complex autoimmune disease affecting millions worldwide, characterized by the immune system mistakenly attacking the body's own cells. It predominantly affects women, especially those aged 15-45, and has a disparate impact on marginalized populations, including Black, Latinx, Indigenous, Asian, and Pacific Islander communities.

To further support research efforts and spread awareness about lupus, the Lupus Research Alliance continues to foster innovative research initiatives. The organization is committed to transforming the future treatment landscape through dedicated funding, promoting scientific talent, and driving discoveries towards improved diagnostics and therapies.

For additional information on this groundbreaking collaboration or to contribute to lupus research, visit the Lupus Research Alliance website and follow on social media.